in 5-15% of patients, additional immunosuppressive agents have been incorporated into the conditioning regimens, such as in vivo Campath-1G monoclonal antibody 12 or We have observed transient elevations of serum alanine transaminase (ALT) levels in patients with aplastic ana-ATG. 3 Allogeneic BMT for severe AA using volunteer unrelated donors is associated with an even higher inciemia who have been treated with antithymocyte globulin (ATG). Out of 18 patient episodes analysed retrodence of graft rejection and GVHD, and ATG is currently being evaluated both pre-BMT to prevent graft rejection spectively over a 12 month period, 15 experienced increases in ALT levels with values ranging from 1.2 to and post-BMT for its anti-GVHD effect. 13 The International BMT Registry (IBMTR) has recently reported that the use 18.5 times the upper limit of normal. In 11 of 15 episodes this was transient with ALT values returning to of ATG in the conditioning regimen for patients with AA due to Fanconi anaemia is an important variable associated normal by 30 days, but in two patients this persisted for 6 months, and in a further two, until death at 34 and with improved survival after HLA-identical sibling and alternative donor BMT.
but we have observed a frequent increase in serum alanine transaminase (ALT) in patients with AA receiving ATG as primary treatment for their disease. This prompted a retroPolyclonal antithymocyte globulin (ATG) is used as an spective analysis of LFT in AA patients treated with ATG immunosuppressive agent in the treatment of aplastic during the last 12 months at our hospital. anaemia, 1 in organ transplantation to treat acute rejection, 2, 3 and to prevent and treat graft-versus-host disease (GVHD) Patients following bone marrow transplantation (BMT). 4 ATG is the treatment of choice for patients with severe
From September 1994 to August 1995, 15 consecutive aplastic anaemia (AA) who are ineligible for BMT from an patients with AA were treated with ATG (Pasteur Merieux) HLA-identical sibling, and for patients with non-severe AA at St George's Hospital. Of these patients, 10 had severe who are transfusion dependent. Response rates of 50-80% AA and five non-severe AA, as defined by Camitta et al.
16
can be achieved when ATG is used alone, in combination The male:female ratio was 8:7 and the median age 49 years with cyclosporine or androgenic steroids, or with granulo-(range 13-79). Twelve patients received one course of ATG cyte colony-stimulating factor (G-CSF). [5] [6] [7] [8] [9] A second course (horse, lymphoglobuline in seven; rabbit, thymoglobuline of ATG may be given if there is no response to the first in five), and three received two courses of ATG (one horse course or following relapse.
10,11 Most commonly a horse and one rabbit in each case). The total number of patient preparation (lymphoglobuline, Pasteur Merieux, Lyon, courses of ATG analysed was 18. The dose of ATG was France) is given for the first course, and rabbit ATG 1.5 vials/10 kg/day (15 mg/kg/day for horse ATG and (thymoglobuline, Pasteur Merieux) is usually reserved for 3.75 mg/kg/day for rabbit ATG), given for 5 days. the second course.
All patients received oral prophylactic fluconazole, cip-AA may be treated with allogeneic BMT. In an attempt rofloxacin and ranitidine. Prior to ATG treatment, three to overcome the problem of graft rejection which occurs patients were taking cyclosporine and one oxymetholone, but these were routinely discontinued before starting ATG. Prednisolone 1 mg/kg/day was commenced on day +5 of Abnormalities of ALT values prior to ATG treatment zoster viral serology were obtained. There were no cases of fungal sepsis, and only two patients had an episode of were documented in four patients. Two of these were taking cyclosporine and ALT values were 2 and 3 times the upper culture positive bacterial septicaemia. limit of normal, respectively. ALT values were just outside the normal range (47 and 52 IU/l respectively, normal range 5-40) in two other patients, one of whom had post-hepatitic Discussion AA (non A, non-B, non-C). An isolated elevation of bilirubin (up to twice the upper limit of normal) before ATG In the setting of BMT, the cause of LFT abnormality is frequently multifactorial and can include sepsis (bacterial, was seen in two other patients.
All patients were screened for acute and chronic infecfungal and viral), GVHD, veno-occlusive disease of the liver and drug toxicity. Patients with AA who are treated tions, namely, hepatitis A, B, C, CMV, EBV and parvovirus. Evidence of recent acute hepatitis A was assessed by with ATG as immunosuppressive therapy instead of BMT, however, are also at risk of hepatotoxicity. specific IgM antibodies, recent or chronic hepatitis B by positivity for hepatitis B surface antigen, recent acute hepa-ATG is highly immunosuppressive producing immediate lymphopenia and temporary worsening of pre-existing neutitis B by positivity for hepatitis B core IgM and hepatitis C infection by a positive antibody test. Recent CMV, EBV, tropenia. In addition, corticosteroids are routinely used to prevent and treat immediate reactions and serum sickness. varicella-zoster and parvovirus was detected by specific IgM. No patient had evidence of acute infection or viral These factors predispose patients to an increased risk of infections during and in the following weeks after ATG reactivation pre-ATG.
treatment.
Reactivation of viruses especially the herpes viruses, has been reported after ATG, although this was not observed Results in our patients. Following renal or cardiac transplantation, CMV infection occurs in 18-51% of patients receiving A transient increase in ALT was observed in 15 out of 18 (83%) patient courses (Figure 1) . The median level of ALT ATG with azathioprine, cyclosporine and/or corticosteroids for prevention or treatment of graft rejection. [17] [18] [19] Because rose from day +4 after finishing ATG and remained abnormal until day +30, but in two patients levels remained elevof the increased risk of infection prophylactic antibiotics and antifungal agents are routinely given during and after ated at 6 months. In a further two patients, ALT levels remained elevated until death for haemorrhage on days 34 ATG treatment. All patients in our study received prophylactic ciprofloxacin and fluconazole, both of which are and 145, respectively. The median day of onset of elevation of ALT from the start of ATG was day 5 (range 1-10).
potentially hepatotoxic. However, the incidence of hepatotoxicity is low: increases in ALT, alkaline phosphatase and The range of elevated ALT was 1.2 to 18.5 times the upper limit of normal, and the median value for maximum ALT ␥ glutamyl transferase are quoted to occur in only 5-7% of patients receiving fluconazole and elevated serum ALT level was 108 (range 49-741). Levels of serum bilirubin and alkaline phosphatase remained within normal limits.
values have been observed in only 2% of patients receiving ciprofloxacin. 20 Out of 18 patient courses of ATG, there There was no difference in the incidence or degree of increase in ALT values between patients receiving horse or were no cases of fungal sepsis, and only two cases of culture-proven bacterial septicaemia, making it unlikely that rabbit ATG. At the time of increase in ALT levels, patients were re-screened for evidence of acute viral infection or systemic infection contributed to the LFT abnormality in most of our patients. reactivation post-ATG, but no positive results from hepatitis A, B, C, CMV, EBV, herpes simplex and varicellaCyclosporine and oxymetholone, are frequently used after ATG treatment as they have been shown to increase the response rate to ATG in patients with AA. 6, 9, 15 Both are potentially hepatotoxic, but usually produce a cholestatic rather than a hepatitic pattern. Only three patients were taking cyclosporine prior to ATG but blood levels were not toxic and the drug was routinely discontinued prior to starting ATG. One patient had been taking oxymetholone prior to ATG but LFTs were normal. No patient received cyclosporine or oxymetholone during ATG or in the immediate 2-3 weeks after ATG.
We are aware of only one report of LFT abnormality after ATG treatment, reported in the patients receiving ATG and methylprednisolone in the control arm of the study reported by Frickhofen et al. 15 A maximum WHO grade of hepatotoxicity of 2 was reported in 39% of patients during the first 21 days after ATG and methylprednisolone. There is some evidence that ATG binds to many human 371-377. tissues including kidney, breast, lung, colon and liver. normalisation of values within a month. In the absence of confers a low incidence of graft-versus-host disease associated an identifiable cause, we conclude that this may represent with a high incidence of mixed chimaerism after bone marrow either a non-specific binding effect of ATG to hepatocytes transplantation for severe aplastic anaemia using HLA identor it may be due to infection with an unidentified agent. 
